{"id":"https://genegraph.clinicalgenome.org/r/12891c90-f444-4290-b01d-9ea5dc23cd88v1.0","type":"EvidenceStrengthAssertion","dc:description":"TAP1 was first reported in relation to autosomal recessive MHC class I deficiency in 1996 (Chen et al., PMID: 8640228). This condition is characterized by chronic upper and lower respiratory bacterial infections, chronic sinusitis, and ulcerating granulomatous skin disease in some cases. Affected individuals typically have normal immunoglobulins, low CD8+ alpha-beta T cells, and activation of natural killer and CD8+ gamma-delta T-cells. Seven variants (nonsense and frameshift) that have been reported in 7 probands in 6 publications (PMIDs: 30189467, 28161407, 18668571, 16624613, 16299152, 10074495) are included in this curation. Variants segregated with disease in three families (PMIDs: 16624613, 28161407, 16299152). Heterozygous parents were unaffected. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is known to be loss of function. This gene-disease relationship is also supported by mouse models, in vitro functional assays, and rescue in patient cells.) (PMIDs: 9952025, 10074495, 11118151). In summary, there is definitive evidence supporting the relationship between TAP1 and autosomal recessive MHC class I deficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen SCID-CID GCEP on the meeting date [July 20, 2023] (SOP Version [9]).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/12891c90-f444-4290-b01d-9ea5dc23cd88","GCISnapshot":"https://genegraph.clinicalgenome.org/r/4f7ee853-d9f3-424e-9108-43931602d6df","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/4f7ee853-d9f3-424e-9108-43931602d6df_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2023-09-21T14:41:05.925Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/4f7ee853-d9f3-424e-9108-43931602d6df_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2023-07-20T17:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4f7ee853-d9f3-424e-9108-43931602d6df_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4f7ee853-d9f3-424e-9108-43931602d6df_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a650ed9-b4f6-46fd-9dc3-61de008f1eae","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f04b9d0-9547-4396-9137-bf3e45dd47d6","type":"Finding","dc:description":"Mouse model showed abnormalities in connections between retina and central targets and nervous system abnormalities. Nervous system and retinal abnormalities have been observed in some patients with TAP1 deficiency.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11118151","rdfs:label":"Mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/36d77cf7-9a9c-4b36-8026-315c2b38e55b","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/042b3065-0120-457f-96ab-930a51feeefd","type":"Finding","dc:description":"Infection with the recombinant vector expressing the TAP1 subunit restored HLA class I expression on the surface of fibroblasts from patient 1 (BRE) and on 40% EBV-B cells from patient 2 (TND-3). The latter partial effect is not surprising as EBV-B cell lines are poorly infected by vaccinia virus. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10074495","rdfs:label":"HLA class I expression rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/4f7ee853-d9f3-424e-9108-43931602d6df_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3f5d840-d369-48a5-b0fc-fdcb9c6f92d6","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52b471e4-d4a5-4047-b418-f7455f948d1c","type":"FunctionalAlteration","dc:description":"Following IL-2, IL-12 and IL-15 stimulation for 3 days, neither NK nor LAK activity against targets lacking class I molecules was induced, suggesting defective recognition of class 1 deficient target cells. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9952025","rdfs:label":"defective recognition of class I-deficient target cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/893cdb31-9084-448e-841c-01e1ab4cfc6d","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f35f430-c80a-40c3-82a7-b31a6c7f6c92","type":"FunctionalAlteration","dc:description":"This study examined the maturation and assembly of HLA class I molecules in cell lines derived from the patients. Neuraminidase treatment did not change the IEF migration pat- tern of samples from HLA class I–deficient cells, showing that the HLA class I heavy chains of these cells were not sialylated. An absence of sialyation indicates that HLA class I molecules cannot reach the distal Golgi compartments and must therefore be blocked in upstream compartments. HLA class I–deficient cells, the quantity of labeled HLA class I molecules decreased during the 4 hours of chase and a barely detectable number (if any; the faint band seen may have been an artifact) of the heavy chains became Endo H–resistant. Altogether, these experiments show that the HLA class I molecules of the class I–deficient cells are peptide-free and consequently remain blocked in the ER.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10074495","rdfs:label":"unstable HLA class I molecules"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5},{"id":"https://genegraph.clinicalgenome.org/r/4f7ee853-d9f3-424e-9108-43931602d6df_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b41f1296-3943-4a3c-9003-b97c9b11fcee_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ca94a4b3-8da2-4b64-bd73-fc6fc30c746f","type":"EvidenceLine","dc:description":"Downgraded because homozygous","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ca94a4b3-8da2-4b64-bd73-fc6fc30c746f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient cells homozygous for this variant had absent HLA 1 expression","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ca94a4b3-8da2-4b64-bd73-fc6fc30c746f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18668571","allele":{"id":"https://genegraph.clinicalgenome.org/r/6eac0bb7-b8ee-483c-90da-cde8a7a4ed1e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000593.6(TAP1):c.2059G>T (p.Glu687Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3746588"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b41f1296-3943-4a3c-9003-b97c9b11fcee","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18668571","rdfs:label":"20 year old female","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/6eac0bb7-b8ee-483c-90da-cde8a7a4ed1e"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"normal percentages of CD19\u0011 B cells, CD3\u0011,CD56\u0011 natural killer (NK) cells, and CD3\u0011 T cells. However, CD8\u0011 T cells represented only 6% of all T lymphocytes (26% in a normal donor)","phenotypes":["obo:HP_0002837","obo:HP_0011109","obo:HP_0200042","obo:HP_0002110"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ca94a4b3-8da2-4b64-bd73-fc6fc30c746f_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c4e53533-8419-4fa2-bef6-c2e9e1d6c38b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7bc5ebae-8a41-4f42-8bdd-7be3b4cf7b3c","type":"EvidenceLine","dc:description":"Downgraded because homozygous","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7bc5ebae-8a41-4f42-8bdd-7be3b4cf7b3c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10074495","allele":{"id":"https://genegraph.clinicalgenome.org/r/9262649d-4e8f-4984-8413-d643f71691eb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000593.6(TAP1):c.599-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA363581767"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c4e53533-8419-4fa2-bef6-c2e9e1d6c38b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10074495","rdfs:label":"TND-3 (patient 2)","allele":{"id":"https://genegraph.clinicalgenome.org/r/9262649d-4e8f-4984-8413-d643f71691eb"},"firstTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7bc5ebae-8a41-4f42-8bdd-7be3b4cf7b3c_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a2b114dc-039a-4a17-83cc-2eaecf627e36_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/938d3d0a-766f-44c4-9ada-ddf72f705996","type":"EvidenceLine","dc:description":"Downgraded to 1 because homozygous","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/938d3d0a-766f-44c4-9ada-ddf72f705996_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16624613","allele":{"id":"https://genegraph.clinicalgenome.org/r/bcf34979-8497-4c09-807b-372063a03b2e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000593.6(TAP1):c.1132C>T (p.Arg378Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3746852"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a2b114dc-039a-4a17-83cc-2eaecf627e36","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16624613","rdfs:label":"Patient 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/bcf34979-8497-4c09-807b-372063a03b2e"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0005425","obo:HP_0010701","obo:HP_0010975","obo:HP_0002110"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/938d3d0a-766f-44c4-9ada-ddf72f705996_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/54804ca8-0560-4add-b676-9c7e4e2c063b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11c0b330-f0df-4793-b29a-5a57601ed013","type":"EvidenceLine","dc:description":"Downgraded to 1 because homozygous","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11c0b330-f0df-4793-b29a-5a57601ed013_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16299152","allele":{"id":"https://genegraph.clinicalgenome.org/r/6c940c2a-575a-40d8-bbbc-d3ff3b2ce630","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000593.6(TAP1):c.1564C>T (p.Gln522Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA137014934"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/54804ca8-0560-4add-b676-9c7e4e2c063b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16299152","rdfs:label":"Parissiadis patient","ageType":"AgeAtReport","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/6c940c2a-575a-40d8-bbbc-d3ff3b2ce630"},"firstTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/11c0b330-f0df-4793-b29a-5a57601ed013_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6bfd452e-d3de-4b34-86c0-3e42b2af39b5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3cea6f69-5fcc-4bda-a300-b21b311517ec","type":"EvidenceLine","dc:description":"Downgraded to 1 because homozygous","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3cea6f69-5fcc-4bda-a300-b21b311517ec_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28161407","allele":{"id":"https://genegraph.clinicalgenome.org/r/44f56eb5-d87b-4b35-bb55-b069d7a93261","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000593.6(TAP1):c.1924dup (p.Gln642ProfsTer27)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2580610767"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6bfd452e-d3de-4b34-86c0-3e42b2af39b5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28161407","rdfs:label":"Case 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/44f56eb5-d87b-4b35-bb55-b069d7a93261"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0002110","obo:HP_0011109"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3cea6f69-5fcc-4bda-a300-b21b311517ec_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3a35b045-a1ea-45ad-99ce-daae1220f976_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7ad514c-7ad1-407f-8f1c-1d2c6288eb92","type":"EvidenceLine","dc:description":"Downgraded because homozygous","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7ad514c-7ad1-407f-8f1c-1d2c6288eb92_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10074495","allele":{"id":"https://genegraph.clinicalgenome.org/r/f4e974f7-0341-49fa-88bd-ac53efa72ce0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000593.6(TAP1):c.639del (p.Trp214GlyfsTer15)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3746970"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3a35b045-a1ea-45ad-99ce-daae1220f976","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10074495","rdfs:label":"BRE (patient 1)","allele":{"id":"https://genegraph.clinicalgenome.org/r/f4e974f7-0341-49fa-88bd-ac53efa72ce0"},"firstTestingMethod":"Other","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/f7ad514c-7ad1-407f-8f1c-1d2c6288eb92_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c375b99e-d2a7-4f21-99fc-a1fe5d237017_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7fcba447-4140-49b6-bfda-4e5cb3dfad6b","type":"EvidenceLine","dc:description":"Downgraded to 1 because homozygous","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7fcba447-4140-49b6-bfda-4e5cb3dfad6b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30189467","allele":{"id":"https://genegraph.clinicalgenome.org/r/be7efdfd-f0c0-429d-bddf-7a04ff42a102","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000593.6(TAP1):c.1699A>T (p.Lys567Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA363591429"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c375b99e-d2a7-4f21-99fc-a1fe5d237017","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30189467","rdfs:label":"4 year old female","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/be7efdfd-f0c0-429d-bddf-7a04ff42a102"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"low CD8+ (T cell) number (86/mm3; normal > 370) with high ratio CD4+/CD8+ (7.3) and normal values of CD19+ (B cell) and natural killer cells (CD16+ and 56+)","phenotypes":["obo:HP_0002110","obo:HP_0002837","obo:HP_0025474","obo:HP_0200042"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/7fcba447-4140-49b6-bfda-4e5cb3dfad6b_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4f7ee853-d9f3-424e-9108-43931602d6df_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1966023-744e-4a29-ab30-1fedae8fa1d3_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16624613","rdfs:label":"Dogu Family","estimatedLodScore":0.85,"family":{"id":"https://genegraph.clinicalgenome.org/r/e1966023-744e-4a29-ab30-1fedae8fa1d3","type":"Family","rdfs:label":"Dogu Family","member":{"id":"https://genegraph.clinicalgenome.org/r/a2b114dc-039a-4a17-83cc-2eaecf627e36"}},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0010701","obo:HP_0010975","obo:HP_0002110","obo:HP_0005425"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/a2b114dc-039a-4a17-83cc-2eaecf627e36"}},{"id":"https://genegraph.clinicalgenome.org/r/8df724fb-f595-4bcd-842a-e2181cb99b97_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28161407","rdfs:label":"Hanalioglu Family","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/8df724fb-f595-4bcd-842a-e2181cb99b97","type":"Family","rdfs:label":"Hanalioglu Family","member":{"id":"https://genegraph.clinicalgenome.org/r/6bfd452e-d3de-4b34-86c0-3e42b2af39b5"}},"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0011109","obo:HP_0002110"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/6bfd452e-d3de-4b34-86c0-3e42b2af39b5"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":6905,"specifiedBy":"GeneValidityCriteria9","strengthScore":17,"subject":{"id":"https://genegraph.clinicalgenome.org/r/J33WdLdpA2c","type":"GeneValidityProposition","disease":"obo:MONDO_0011476","gene":"hgnc:43","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_4f7ee853-d9f3-424e-9108-43931602d6df-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}